Furthermore, we validate the anti-cancer activity of this approach in patient-derived pancreatic cancer organoids with the KRAS G12D mutation, demonstrating the clinical translation potential of our approach for the treatment of KRAS-addicted cancers. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.